Scynexis Inc
Research Scynexis Inc (SCYX) on Bullrun: market cap USD 51.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSCYX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 51.64M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 21.30M
- Free cash flow-USD 5.92M
Valuation Snapshot
latest market cap is USD 51.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 20.60M | -USD 8.61M | -USD 5.28M | n/a | -0.17 | USD 21.26M | USD 2.18M | USD 49.38M |
| FY2024 | USD 3.75M | -USD 21.29M | -USD 24.01M | 100.0% | -0.44 | USD 16.05M | USD 16.27M | USD 55.08M |
| FY2023 | USD 140.14M | USD 67.04M | n/a | n/a | 1.39 | USD 34.05M | USD 15.08M | USD 72.96M |
| FY2022 | USD 5.09M | -USD 62.81M | n/a | n/a | -1.47 | USD 45.81M | USD 34.16M | USD 3.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 51.64M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 27.43M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 45.95M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 82.97M | 1.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 50.94M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 175.10M | n/a | n/a | n/a |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Scynexis Inc's market cap?
Scynexis Inc's market capitalization is USD 51.64M.
What does Scynexis Inc do?
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc.